KR20220057669A - Compositions for Anti-Bacterial and Anti-Inflammatory Effect Comprising Oil of Ulvoid green algae - Google Patents

Abstract

The present invention relates to an antibacterial and anti-inflammatory composition including green algae oil as an active ingredient. According to the present invention, the composition including green algae oil has low toxicity and excellent antibacterial activity. In addition, the composition including green parsley oil of the present invention has no cytotoxicity and effectively inhibits production of inflammatory cytokine so as to be effectively used for treatment and prevention of inflammatory diseases. Therefore, the composition of the present invention can be usefully used for antibacterial and anti-inflammatory purposes in various fields such as cosmetics, medicines, health functional foods and the like.

Description

Compositions for Anti-Bacterial and Anti-Inflammatory Effect Comprising Oil of Ulvoid green algae

The present invention relates to an antibacterial and anti-inflammatory composition comprising green seaweed oil as an active ingredient.

The inflammatory response is a series of immune responses that are inevitably caused by activated immune cells as a defensive response that occurs when a living tissue is damaged. It is known that nitric oxide (NO) and pro-inflammatory cytokines produced by activating immune cells are involved in the inflammatory response. In addition, COX-2 (cyclooxygenase-2) is an enzyme that catalyzes the production of PGE2 (prostaglandin E2), an inflammatory mediator, from arachidonic acid, and plays an important role in the inflammatory reaction. Therefore, suppression of NO production or iNOS, COX-2, IL-1β and TNF-α expression and inhibition of reactive oxygen species by inflammation are important goals in treating inflammatory diseases.

Steroidal anti-inflammatory drugs used to treat inflammatory diseases cause side effects such as glaucoma, cataracts, hypertension, bipolar disorder, weight gain, diabetes and osteoporosis. In recent years, there is a demand for the development of a substance derived from a natural substance that has no or little risk of side effects or cytotoxicity, and which can effectively suppress inflammation.

On the other hand, loss due to spoilage during the food distribution process in the food industry by pathogenic microorganisms, harmfulness and environmental pollution due to the use of excessive chemical pesticides on crops in the agricultural industry, and the emergence of antibiotic-resistant strains due to the misuse of antibiotics, etc. There is damage in society as a whole. Antibacterial agents, which are substances that have an antibacterial action against microorganisms, are widely used to treat diseases caused by bacterial infections, and have been prepared mainly by separating them from natural products including mold or by chemically synthesizing them. Most of the currently used antibiotics are manufactured through chemical synthesis and have many limitations, such as high cost and side effects.

Recently, in order to solve various problems caused by the use of chemical antibacterial agents, research on this is made as a major task to develop an antibacterial composition using a natural product extract, but in most natural product extracts, microorganisms having an antibacterial effect Although there is a limited and antibacterial effect, the function appears at a very high concentration, so it is often necessary to use it in combination with an additional antibacterial agent.

On the other hand, in the case of krill oil, it was in the limelight as a natural material with excellent antibacterial and anti-inflammatory effects, but as the excellence and efficacy of krill oil became known and demand surged, about 80% of krill, which converted carbon dioxide into carbon, decreased, causing global warming. There are reports that it is accelerating. In addition, since the decrease in krill, which is food for whales and penguins, threatens the survival of the marine animals, it is urgent to find an alternative material for krill oil.

Under this background, the present inventors conducted research on natural materials with excellent antibacterial and anti-inflammatory effects, and paid special attention to the antibacterial and anti-inflammatory effects of green seaweed among seaweeds to further improve their antibacterial and anti-inflammatory effects. , by investigating the excellent antibacterial and anti-inflammatory effects of green seaweed oil, and completed the present invention.

KR 10-0846356 B

An object to be solved by the present invention is to provide an antibacterial and anti-inflammatory composition containing as an active ingredient green seaweed oil, which is applicable to the skin, is harmless to the human body, has excellent safety, and has excellent anti-inflammatory and antibacterial effects.

The present invention for achieving the above object relates to an antibacterial and anti-inflammatory food composition comprising green seaweed oil as an active ingredient.

In addition, the present invention relates to a cosmetic composition for antibacterial and anti-inflammatory comprising green seaweed oil as an active ingredient.

In addition, the present invention relates to a pharmaceutical composition for antibacterial and anti-inflammatory comprising green seaweed oil as an active ingredient.

In addition, the present invention relates to a method for preparing an antibacterial and anti-inflammatory composition comprising green seaweed oil as an active ingredient.

The composition comprising green seaweed oil of the present invention has low toxicity and excellent antibacterial activity. In addition, the composition comprising the green seaweed oil of the present invention has no cytotoxicity and effectively inhibits the production of inflammatory cytokines, so that it can be effectively used for the treatment and prevention of inflammatory diseases. Therefore, the composition of the present invention can be usefully used for antibacterial and anti-inflammatory purposes in various fields such as cosmetics, medicine, and health functional food.

1 is a photograph showing the antibacterial activity of green seaweed oil according to Examples 1 to 3 of the present invention.
Figure 2a is a photograph confirming the change in antibacterial activity by enzymatic treatment of seaweed oil according to Example 1 (Gimnyeongsan green seaweed, Jeju), and FIG. is a photograph confirming the change in antibacterial activity by

Hereinafter, the present invention will be described in detail.

According to one aspect of the present invention, the present invention provides an antibacterial and anti-inflammatory food composition comprising green seaweed oil as an active ingredient.

Green seaweed is a kind of green algae that is widely distributed around the world, and mainly lives by attaching to rocks on the coast. In particular, it has been used as food for a long time in Europe, and studies on various food and physiological activities have been reported. One of the main characteristics of brown seaweed is that it contains a large amount of polysaccharide containing a sulfate group, and this acidic polysaccharide has been reported to have antitumor, antiviral, immune-enhancing effects, and anticoagulant action of blood. In Korea, the anticancer effect and immune activity of glycoproteins extracted from algae have been reported.

In the present invention, the green seaweed ( Ulva ohnoi ), green seaweed ( Ulva pertusa ), bent brown seaweed ( Ulva flexousa ), long-tong brown seaweed ( Ulva procera ), peony brown seaweed ( Ulva conglobata ), green brown seaweed ( Ulva japonica ), Ulva intestinalis , Ulva compressa , Ulva prolifera , Ulva clathrata , Enteromorpha linza , Monostroma nitidum , and Monostroma gre It may be at least one selected from among, and preferably, large brown seaweed ( Ulva ohnoi ), hole brown seaweed ( Ulva pertusa ), bent brown seaweed ( Ulva flexousa ), long long brown seaweed ( Ulva procera ), peony brown seaweed ( Ulva conglobata ), green brown seaweed ( Ulva ) japonica ), algae ( Ulva intestinalis ), flat seagrass ( Ulva compressa ), prickly seagrass ( Ulva prolifera ) and lattice blue ( Ulva clathrata ) may be at least one selected from, more preferably large brown seaweed ( Ulva ohnoi ), hole It may be one or more selected from brown seaweed ( Ulva pertusa ), bent brown seaweed ( Ulva flexousa ), long brown seaweed ( Ulva procera ), and peony galvanae ( Ulva conglobata ), and even more preferably, it may be large brown seaweed ( Ulva ohnoi ).

The seaweed oil may be an oil extracted after performing microwave drying of seaweed. The green seaweed oil extracted after performing the microwave drying is more preferable in terms of antibacterial and anti-inflammatory effects than the oil extracted after performing freeze-drying, vacuum drying, and the like.

Specifically, the microwave drying may be performed using a microwave dryer of 15 to 20 kW output, and is preferably performed once or twice for 1 minute to 3 minutes.

The moisture content of the green onion after the microwave drying may be 3 to 10% by weight, preferably 4 to 8% by weight, more preferably 5 to 7% by weight.

The green seaweed oil may be an oil extracted according to any one method selected from compression method, steam distillation method, cold soaking method, warm soaking method, solvent extraction method, and supercritical carbon dioxide extraction method, preferably oil extracted by supercritical carbon dioxide extraction method can

In one embodiment, the flow rate of carbon dioxide during the supercritical extraction may be 50 to 70 ㎖ / min.

In addition, the supercritical extraction temperature may be 45 to 55 ℃, the pressure may be 270 to 290 bar.

In a broad sense, the seaweed oil of the present invention includes a processed product formulated so that the seaweed oil itself can be administered to the human body. Although the experiment was carried out with seaweed oil in the present invention, it will be expected by those skilled in the art that the desired effect can be achieved even in the same form as a processed seaweed oil.

The seaweed oil exhibits antibacterial activity against at least one strain selected from Bacillus subtilis and Escherichia coli . In addition, the seaweed oil can prevent, improve or treat diseases such as food poisoning typically induced by the subtilis ( Bacillus subtilis ) and Escherichia coli ( Escherichia coli ).

In addition, the green seaweed oil may exhibit an effect of inhibiting the expression of inflammatory cytokines TNF-α or IL-1β. This means that the green seaweed oil according to the present invention is useful for preventing, ameliorating or treating inflammatory diseases without side effects. Specific examples of inflammatory diseases that can be prevented, improved or treated by applying the composition of the present invention include inflammatory bowel disease, inflammatory collagen vascular disease, glomerulonephritis, inflammatory skin disease, sarcoidosis, retinitis, gastritis, hepatitis, enteritis, Arthritis, tonsillitis, pharyngitis, bronchitis, pneumonia, pancreatitis, sepsis and nephritis, etc. may be present, preferably inflammatory bowel disease or inflammatory skin disease, and more preferably inflammatory bowel disease.

In particular, "inflammatory bowel disease (IBD)" refers to a disease that causes chronic inflammation in the gastrointestinal tract, accompanied by symptoms such as abdominal pain, fever, diarrhea, and bleeding. Specifically, the inflammatory bowel disease may be colitis, but is not limited thereto. The inflammatory bowel disease may specifically be ulcerative colitis or Crohn's disease. The ulcerative colitis is a type of diffuse nonspecific inflammation that mainly invades the mucous membrane and forms bruises or ulcers, the cause of which is not clearly known, and causes various systemic symptoms including bloody diarrhea. do. The Crohn's disease is a granulomatous inflammatory lesion that discontinuously causes ulcers, fibrosis, stenosis, and lesions in the mucous membrane of the entire digestive tract from the oral cavity to the anus. accompanying

The antibacterial and anti-inflammatory food composition of the present invention includes all forms of nutritional supplements, health functional food, food additives and feed, and includes animals including humans or livestock. target for eating.

The food composition may be formulated in the form of capsules, tablets, powders, granules, liquids, pills, flakes, pastes, syrups, gels, jellies, or bars of the green seaweed oil of the present invention. The food composition has the advantage of not having side effects that may occur during long-term administration, unlike general drugs.

In addition, the food composition can be prepared in various forms according to conventional methods known in the art. Common foods include, but are not limited to, beverages (including alcoholic beverages), fruits and their processed foods (eg, canned fruit, bottled, jam, marmalade, etc.), fish, meat and their processed foods (eg, ham, sausages) Corned beef, etc.), breads and noodles (eg udon noodles, soba noodles, ramen, spagate, macaroni, etc.), fruit juice, various drinks, cookies, syrup, dairy products (eg butter, cheese, etc.), edible vegetable oils and fats, margarine , vegetable protein, retort food, frozen food, various seasonings (eg, soybean paste, soy sauce, sauce, etc.) can be prepared by adding the green seaweed oil. In addition, the nutritional supplement is not limited thereto, but may be prepared by adding the green seaweed oil to capsules, tablets, pills, and the like. In addition, the health functional food is not limited thereto, but for example, the green seaweed oil itself can be prepared in the form of tea, juice, and drink, and can be liquefied for drinking (health drink), granulated, encapsulated and powdered. can be ingested. In addition, in order to use the green seaweed oil in the form of a food additive, it may be prepared as a powder or extracted and then used in the form of a concentrate.

When the antibacterial and anti-inflammatory food composition of the present invention is used as a health drink composition, the health drink composition may contain various flavoring agents or natural carbohydrates as additional ingredients, like a conventional drink. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrin and cyclodextrin; It may be a sugar alcohol such as xylitol, sorbitol, or erythritol. Sweeteners include natural sweeteners such as taumatine, stevia extract; A synthetic sweetener such as saccharin or aspartame may be used. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention.

The green seaweed oil of the present invention may be contained as an active ingredient in the food composition, and the amount may be an amount effective to achieve antibacterial and anti-inflammatory effects, and is not particularly limited, but 0.01 to 100 weights based on the total weight of the composition % is preferred. The food composition of the present invention can be prepared by mixing green seaweed oil with other active ingredients known to have antibacterial or anti-inflammatory effects.

In addition to the above, the food composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid, pectic acid salts, alginic acid, alginic acid salts, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, It may contain glycerin, alcohol or a carbonation agent and the like. In addition, the health food of the present invention may contain fruit for the production of natural fruit juice, fruit juice beverage, or vegetable beverage. These components may be used independently or in combination. The proportion of these additives is not particularly important, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

In addition, another aspect of the present invention relates to an antibacterial and anti-inflammatory cosmetic composition comprising green seaweed oil as an active ingredient.

In the present specification, the contents of "green seaweed oil", "antibacterial" and "anti-inflammatory" are the same as described above.

In the present invention, "contained as an active ingredient" means to contain an effective amount of a cosmetic composition capable of exhibiting antibacterial and anti-inflammatory effects on the skin.

In an exemplary embodiment, the green seaweed oil may be present in the composition in any amount desired to provide effective antibacterial and anti-inflammatory efficacy. According to one aspect, the green seaweed oil may be 0.0001 to 99.9% by weight, 0.001 to 30% by weight, preferably 0.01 to 10% by weight, more preferably 0.1 to 10% by weight, even more preferably 0.1 to 5% by weight % may be included. According to another embodiment, the green seaweed oil may be contained in an amount of preferably 0.001 to 300 mg/mL, more preferably 0.01 to 200 mg/mL, based on the total volume of the composition.

When the content of the seaweed oil is less than the above range, it is difficult to expect the effect of the seaweed oil. there is That is, by including the green seaweed oil of the present invention in the above range, excellent antibacterial and anti-inflammatory effects can be realized, formulation and product stability can be achieved, and excellent effects can be exhibited with an optimal content in terms of economic feasibility. According to a preferred aspect of the present invention, the formulation of the antibacterial and anti-inflammatory cosmetic composition is composed of a lotion, emulsion, cream, essence, cosmetic ointment, spray, gel, pack, sunscreen, makeup base, foundation, powder and makeup remover. It may be selected from the group.

According to a preferred aspect of the present invention, the antibacterial and anti-inflammatory cosmetic composition may additionally include a dermatologically acceptable excipient in addition to the green seaweed oil.

The excipient is not limited thereto, but may include, for example, an emollient, a skin penetration enhancer, a colorant, a fragrance, an emulsifier, a thickening agent, and a solvent. In addition, fragrances, dyes, bactericides, antioxidants, preservatives and moisturizing agents may be additionally included, and for the purpose of improving physical properties, thickeners, inorganic salts, synthetic polymer materials, and the like may be included.

According to a preferred embodiment of the present invention, the moisturizing agent is glycerin, butylene glycol, propylene glycol, sorbitol, hexylene glycol, dipropylene glycol, diglycerin, 1,2-hexanediol, panthenol, betaine, squalane, petrolatum, fluid It may be at least one selected from paraffin and hydrolyzed wheat gluten, but is not limited thereto.

The cosmetic composition of the present invention may be used alone or in overlapping application, or may be used in overlapping application with other cosmetic compositions other than the present invention. In addition, the cosmetic composition according to the present invention can be used according to a conventional method of use, and the number of times of use can be varied according to the skin condition or taste of the user.

In addition, another aspect of the present invention relates to an antibacterial and anti-inflammatory pharmaceutical composition comprising green seaweed oil as an active ingredient.

In the present specification, the contents of "green seaweed oil", "antibacterial" and "anti-inflammatory" are the same as described above.

The pharmaceutical composition is one selected from inflammatory bowel disease, inflammatory collagen vascular disease, glomerulonephritis, inflammatory skin disease, sarcoidosis, retinitis, gastritis, hepatitis, enteritis, arthritis, tonsillitis, pharyngitis, bronchitis, pneumonia, pancreatitis, sepsis and nephritis It is possible to prevent or treat the above inflammatory diseases.

The antibacterial and anti-inflammatory pharmaceutical composition of the present invention may be prepared using a pharmaceutically suitable and physiologically acceptable adjuvant in addition to the green seaweed oil, and the adjuvant includes an excipient, a disintegrant, a sweetener, a binder, a coating agent, A swelling agent, a lubricant, a lubricant, or a flavoring agent may be used.

In addition, the antibacterial and anti-inflammatory pharmaceutical composition of the present invention can be formulated by including one or more pharmaceutically acceptable carriers.

The pharmaceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration.

Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like.

Carriers for parenteral administration may also include water, suitable oils, saline, aqueous glucose and glycols, and the like. In addition, it may further include a stabilizer and a preservative. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives are benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. As other pharmaceutically acceptable carriers, reference may be made to those described in the following literature (Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).

The pharmaceutical composition of the present invention may be administered to mammals including humans by any method. For example, it may be administered orally or parenterally, and parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal. , intranasal, enteral, topical, sublingual or rectal administration.

The pharmaceutical composition of the present invention may be formulated as a formulation for oral administration or parenteral administration according to the administration route as described above. When formulated, one or more buffers (eg, saline or PBS), antioxidants, bacteriostatic agents, chelating agents (eg, EDTA or glutathione), fillers, bulking agents, binders, adjuvants (eg, aluminum hydroxide) side), suspending agents, thickening agents, wetting agents, disintegrating agents or surfactants, diluents or excipients.

Formulations for oral administration include tablets, pills, powders, granules, liquids, gels, syrups, slurries, suspensions or capsules, and such solid preparations include at least one excipient, for example, in the pharmaceutical composition of the present invention. , Starch (including corn starch, wheat starch, rice starch, potato starch, etc.), calcium carbonate, sucrose, lactose, dextrose, sorbitol, mannitol, xylitol, erythritol maltitol, cellulose , methyl cellulose, sodium carboxymethyl cellulose, and hydroxypropylmethyl-cellulose or gelatin may be mixed and prepared. For example, tablets or dragees can be obtained by combining the active ingredient with solid excipients, grinding them, adding suitable auxiliaries, and processing them into a mixture of granules.

In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Liquid formulations for oral use include suspensions, solutions, emulsions, or syrups. In addition to water or liquid paraffin, which are commonly used simple diluents, various excipients, for example, wetting agents, sweeteners, flavoring agents, or preservatives may be included. .

In addition, in some cases, cross-linked polyvinylpyrrolidone, agar, alginic acid or sodium alginate may be added as a disintegrant, and an anti-aggregating agent, a lubricant, a wetting agent, a flavoring agent, an emulsifier, and a preservative may be additionally included. .

When administered parenterally, the pharmaceutical composition of the present invention may be formulated according to methods known in the art in the form of injections, transdermal administrations and nasal inhalants together with suitable parenteral carriers. In the case of the injection, it must be sterilized and protected from contamination by microorganisms such as bacteria and fungi. For injection, examples of suitable carriers include, but are not limited to, water, ethanol, polyols (eg, glycerol, propylene glycol and liquid polyethylene glycol, etc.), mixtures thereof, and/or a solvent or dispersion medium containing vegetable oil. can More preferably, suitable carriers include Hanks' solution, Ringer's solution, phosphate buffered saline (PBS) with triethanolamine or isotonic solutions such as sterile water for injection, 10% ethanol, 40% propylene glycol and 5% dextrose. etc. can be used. In order to protect the injection from microbial contamination, it may further include various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In addition, in most cases, the injection may further contain an isotonic agent such as sugar or sodium chloride.

In the case of transdermal administration, forms such as ointment, cream, lotion, gel, external solution, pasta, liniment, and air are included. As used herein, "transdermal administration" means that an effective amount of the active ingredient contained in the pharmaceutical composition is delivered into the skin by topically administering the pharmaceutical composition to the skin.

For administration by inhalation, it is dispensed from a pressurized pack or nebulizer using a propellant suitable for the composition according to the invention, for example dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. It can be conveniently delivered in the form of an aerosol spray. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. For example, gelatin capsules and cartridges for use in inhalers or insufflators may be formulated to contain a powder mixture of a suitable powder base, such as lactose or starch. Formulations for parenteral administration are described in Remington's Pharmaceutical Science, 15th Edition, 1975. Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour, a recipe commonly known to all pharmaceutical chemistry.

The pharmaceutical composition of the present invention can provide desirable antibacterial and anti-inflammatory effects when it contains green seaweed oil in an effective amount. In the present specification, the term 'effective amount' refers to an amount that shows a higher reaction than the negative control, and preferably refers to an amount sufficient to exhibit antibacterial and anti-inflammatory effects. The pharmaceutical composition of the present invention may contain 0.01 to 99.99% of green seaweed oil, and the remaining amount may be occupied by a pharmaceutically acceptable carrier. The effective amount of green seaweed oil included in the pharmaceutical composition of the present invention will vary depending on the form in which the composition is commercialized.

The total effective amount of the pharmaceutical composition of the present invention may be administered to a patient as a single dose, and may be administered by a fractionated treatment protocol in which multiple doses are administered for a long period of time. . The pharmaceutical composition of the present invention may vary the content of the active ingredient depending on the severity of the disease. When administered parenterally, it is preferably administered in an amount of 0.01 to 500 mg, more preferably 0.1 to 300 mg per 1 kg of body weight per day based on the green seaweed oil, and when administered orally, it is administered in an amount of green seaweed oil per day It may be administered in 1 to several divided doses so as to be administered in an amount of preferably 0.01 to 1000 mg, more preferably 0.01 to 500 mg per kg of body weight. However, the effective dosage for the patient is determined by considering various factors such as the age, weight, health status, sex, severity of disease, diet and excretion rate of the patient, as well as the administration route and number of treatments of the pharmaceutical composition, as well as the dosage of the green seaweed oil. Therefore, considering this point, those of ordinary skill in the art will be able to determine an appropriate effective dosage of the green seaweed oil according to the antibacterial and anti-inflammatory effects. The pharmaceutical composition according to the present invention is not particularly limited in its formulation, administration route and administration method as long as the effect of the present invention is exhibited.

In addition, another aspect of the present invention comprises the steps of (1) preparing a drying material by drying green onion; And (2) extracting the oil from the dry material; relates to a method for producing an antibacterial and anti-inflammatory food composition comprising a.

In the present specification, the contents of the "green seaweed oil", "antibacterial", "anti-inflammatory" and "food composition" are the same as described above.

In addition, another aspect of the present invention comprises the steps of (1) preparing a drying material by drying green onion; And (2) extracting the oil from the dry material; relates to a method for producing a cosmetic composition for antibacterial and anti-inflammatory comprising a.

In the present specification, the contents of the “green seaweed oil”, “antibacterial”, “anti-inflammatory” and “cosmetic composition” are the same as described above.

In addition, another aspect of the present invention comprises the steps of (1) preparing a drying material by drying green onion; And (2) extracting the oil from the dry material; relates to a method for producing a pharmaceutical composition for antibacterial and anti-inflammatory comprising a.

In the present specification, the contents of the "green seaweed oil", "antibacterial", "anti-inflammatory" and "pharmaceutical composition" are the same as described above.

Hereinafter, the present invention will be described in detail with reference to examples, but the present invention is not limited by the following examples.

< Examples and Comparative Examples>

Example 1: Preparation of Green Seaweed Oil - Supercritical Carbon Dioxide Extraction

After obtaining blueberries from Gimnyeong, Jeju ( Ulva ohnoi ), they were washed with purified water and dehydrated. After that, 1 kg of green seaweed is put into a rotary microwave dryer with 17 kW output and operated for 2 minutes, then restarted for 2 minutes to adjust the moisture content to about 6 wt%, and then dried by pulverizing it to a particle size of 0.5 m The material was prepared.

Thereafter, a supercritical fluid extractor (SFX 3560, ISCO Lincoln, USA) was used to extract supercritical carbon dioxide from the dried green seaweed, and a flow rate of supercritical carbon dioxide was introduced at 280 bar and 50 ° C. at a rate of 60 mL/min. and extracted for 1 hour.

After the extraction was completed, the carbon dioxide inside the extraction tank was removed, the pressure was removed, and the supercritical fluid extract was recovered. A total of 25.0 g of green seaweed oil was obtained from the recovered extract using a rotary vacuum concentrator.

Example 2: Preparation of green seaweed oil

Seaweed oil was prepared in the same manner as in Example 1, except that green seaweed from Jeju Seopji ( Ulva ohnoi ) was used instead of seaweed from Gimnyeong from Jeju.

Example 3: Preparation of green seaweed oil

Seaweed oil was prepared in the same manner as in Example 1, except that green onions from Jocheon, Jeju ( Ulva ohnoi ) were used instead of green onions from Gimnyeong from Jeju.

Comparative Example 1: Preparation of hot water extract of green onion

It was carried out in the same manner as in Example 1, but instead of supercritical carbon dioxide extraction, hot water extraction was performed to prepare a green onion extract.

In the hot water extraction method, specifically, 15 times the weight of purified water was added to the dried green seaweed, extracted under reflux at 60° C. for 4 hours in a reflux bath, and cooled. Thereafter, after filtration with 6 μm filter paper (whatman #3), it was concentrated under rotary pressure and freeze-dried, and used for efficacy evaluation.

Comparative Example 2: Preparation of methanol extract of green onion

It was carried out in the same manner as in Example 1, except that the extraction with methanol instead of supercritical carbon dioxide extraction was performed to prepare a green onion extract.

In the methanol extraction, specifically, 15 times the weight of methanol was added to the dried green onion material, followed by extraction by stirring at room temperature for 5 hours. Thereafter, after filtration with 6 μm filter paper (whatman #3), it was concentrated under rotary pressure and freeze-dried, and used for efficacy evaluation.

Comparative Example 3: Preparation of green seaweed oil - use of freeze-drying

It was carried out in the same manner as in Example 1, but by freeze-drying instead of microwave drying to prepare green seaweed oil.

Comparative Example 4: Preparation of green seaweed oil - using vacuum drying

It was carried out in the same manner as in Example 1, but by vacuum drying instead of microwave drying, green seaweed oil was prepared.

Comparative Example 5: Krill Oil

Krill oil (containing 100 IU of vitamin A, 0.5 IU of vitamin E, choline 73 mg, omega 3 fatty acid 300 mg, omega 6 fatty acid 20 mg, astaxanthin 1.5 mg per 1 g) is manufactured by Neptune, Canada Technologies & Bioressources Inc.) was used.

<Test Example>

Test Example 1: Measurement of total polyphenol content

Total polyphenol content was measured according to Singleton and Rossi (1965) method using Folin-Denis reagent.

1 ㎖ of 0.2 N folin-ciocalteu reagent was mixed with 200 μl of green seaweed oil (or extract) according to Examples and Comparative Examples, and then reacted for 4 minutes. Then, 800 μl of a 7.5% Na ₂ CO ₃ solution was added to prepare a concentration of 0.1 mg/ml, and then reacted for 2 hours at room temperature by blocking light, and absorbance was measured at 620 nm using a spectrophotometer. Gallic acid was used as a standard reagent, polyphenol content was calculated using a standard curve, and krill oil was used as a control material. Total polyphenol content was calculated as gallic acid equivalents (mg GAE) per sample (g).

division Total polyphenol content (mg GAE/g) Example 1 79.2±0.12 Example 2 88.7±0.09 Example 3 80.4±0.23 Comparative Example 1 72.9±0.07 Comparative Example 2 75.3±1.12 Comparative Example 3 71.3±0.39 Comparative Example 4 73.4±0.21 Comparative Example 5 72.5±1.04

Looking at Table 1, it can be seen that the green seaweed oil according to the embodiment of the present invention has a significantly higher polyphenol content compared to Comparative Examples 1 to 4, and also shows a higher polyphenol content than the krill oil of Comparative Example 5. .

Test Example 2: Measurement of antibacterial activity

2-1: Measurement of antibacterial activity using URDA method

Antibacterial activity was measured using the URDA (ultrasensitive radial diffusion assay) method.

The strains used in the experiment were Gram-positive bacteria Bacillus subtilis KCTC1021, Gram-negative bacteria Escherichia coli D31 and fungi Candidia albicans KCTC76965 were used. Pre-culture was performed at ℃. The activated bacteria were prepared by measuring the absorbance at 630 nm so that the OD value of the bacteria was 0.01 (≒ 0.5 McF). 0.03% TSB, SDB (sabouraud's dextrose broth), 1% agarose, and 10 mM phosphate buffer (pH 6.5) were added to a 9.5 ml underlay gel with 500 μl of the diluted bacterial solution at each concentration, and poured onto a plate to harden. A hole having a diameter of 2.5 mm was drilled in the hardened plate, and 5 μl of a 10 mg/ml concentration of green seaweed oil (or extract) sample according to Examples and Comparative Examples was injected into each well. For all samples, 5 μl of 0.01% acetic acid was used, and it was confirmed that there was no effect by the solvent. After primary incubation at 37°C for 3 hours, 10 ml of overlay gel containing 6% TSB, SDB, 1% agarose and 10 mM phosphate buffer (pH 6.5) was poured and hardened at room temperature, followed by 24 at 37°C. After secondary incubation for a period of time, the size of the clear zone formed in the well was confirmed and shown in Table 2 below. Each experiment was repeated three times, and the data shown in Table 2 below is an average value thereof.

division clear zone size(mm ² ) B. subtilis E. coli C. albicans Example 1 42.71 122.33 none Example 2 73.37 91.81 5.52 Example 3 56.16 110.41 none Comparative Example 1 39.53 97.65 none Comparative Example 2 55.61 49.21 none Comparative Example 3 32.95 61.01 none Comparative Example 4 52.52 58.46 none Comparative Example 5 26.14 74.02 none

1 is a photograph showing the antibacterial activity of green seaweed oil according to Examples 1 to 3 of the present invention.

Referring to Table 2 and FIG. 1, the green seaweed oil according to Examples 1 to 3 of the present invention exhibited strong antibacterial activity against B. subtilis and E. coli , and did not show significant antibacterial activity against the fungus C. albicans . confirmed that it is not.

2-2: Characterization of antibacterial active substances using enzyme treatment

In order to confirm the properties of substances exhibiting antibacterial activity in the green seaweed oil (or extract) according to Examples and Comparative Examples, it was confirmed whether there was a change in antibacterial activity by treatment with various enzymes. 5 μl of green seaweed oil (or extract) at a concentration of 10 mg/ml according to Examples and Comparative Examples, trypsin ('T'; protease), chymotrypsin ('C'; protease), lipase ('L'; lipolytic enzyme), α-amylase ('A'; carbohydrate-degrading enzyme), pronase ('P'; proteolytic enzyme), and proteinase K ('K'; After primary incubation for hours, secondary incubation was performed at 37°C for 24 hours. The cultured extracts were subjected to URDA experiments against B. subtilis , E. coli D31 and C. albicans strains.

2 is a change in antibacterial activity after each treatment with six enzymes (trypsin, chymotrypsin, lipase, α-amylase, pronase and proteinase K) in green seaweed oil according to Examples 1 to 3 of the present invention; This is a picture to confirm. Specifically, Figure 2a is a photograph confirming the change in antibacterial activity by enzymatic treatment of seaweed oil according to Example 1, and Figure 2b is a photograph confirming the change in antibacterial activity by enzymatic treatment of seaweed oil according to Example 2 It is a photograph, and FIG. 2c is a photograph confirming the change in antibacterial activity by enzymatic treatment of green seaweed oil according to Example 3.

Referring to FIG. 2, it can be seen that the antibacterial activity of green seaweed oil according to the present invention is not significantly affected by various enzyme treatments. Therefore, it is inferred that the substance exhibiting antibacterial activity in the green seaweed oil of the present invention is an organic compound, not a carbohydrate, fat, or proteinaceous substance that is cut by enzyme treatment, and it is judged to have stability against the enzyme reaction.

Test Example 3: Measurement of inflammatory cytokine expression in inflammatory bowel disease mouse model

laboratory animal

C57/BL6 mice (28-30 g, 12 weeks old, male) were purchased from Coretech Co., Ltd. (Pyeongtaek, Gyeonggi-do) and used for the experiment after being acclimatized to a breeding box for experimental animals for a week, and the breeding of animals was carried out at a temperature of 23 It was carried out under the conditions of ±1℃, humidity 55±5%, light-dark cycle (light on from 07:00 to 19:00), and illumination of 3000 Lux. It was conducted with the approval of the Ethics Committee.

Induction of inflammatory bowel disease and measurement of inflammatory cytokine expression

The experimental animals were weighed after an adaptation period for one week and classified into 6 arbitrary groups, specifically, a normal group, a DSS (Dextran Sulfate Sodium) group, a DSS+Example 1 group, and a DSS+Comparative Example 1 group. , DSS+Comparative Example 2 administration group, DSS+Comparative Example 3 administration group, each group was divided into 6 animals.

The green seaweed oil or green seaweed extract of Examples and Comparative Examples was prepared at a concentration of 25 mg/kg using distilled water, and the krill oil of Comparative Example 5 was prepared at a concentration of 100 mg/kg.

Thereafter, 100 μl of each sample was orally administered to the experimental animals of each experimental group every day for 10 days.

Experimental groups excluding the normal group were allowed to freely drink 5% DSS dissolved in distilled water from the 4th day of sample administration to induce inflammatory bowel disease (colitis), and the normal group was allowed to freely ingest water.

Thereafter, the colon tissues of the experimental animals were extracted and the expression of inflammatory cytokines was measured using an ELISA kit, and it is shown in Table 3 below.

division Inflammatory cytokine production (pg/mL) TNF-α IL-1β Negative control group (untreated group) 62.2±0.25 51.5±0.94 Positive control group (DSS treatment group) 608.1±40.4 212.6±64.8 Example 1 52.3±10.4 56.8±12.6 Example 2 43.9±20.2 54.7±14.1 Example 3 50.7±13.8 58.1±11.7 Comparative Example 1 112.1±17.4 116.2±21.3 Comparative Example 2 73.2±8.6 94.7±15.8 Comparative Example 3 98.4±5.2 110.9±7.7 Comparative Example 4 89.5±10.5 94.1±12.1 Comparative Example 5 175.3±40.4 106.8±32.8

Referring to Table 4, it can be seen that the green seaweed oil according to the embodiment of the present invention significantly reduces the production of inflammatory cytokines TNF-α and IL-1β compared to the comparative example.

From the above results, it can be confirmed that the green seaweed oil of the present invention has remarkably high antibacterial and anti-inflammatory effects.

Preparation examples for the green seaweed oil of the present invention are exemplified below.

<Production Example>

Preparation Example 1: Preparation of health functional food

1-1: powdered health functional food

100 mg of green seaweed oil of Example 2

appropriate amount of vitamin mixture

70 μg vitamin A acetate

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

Vitamin B2 0.15 mg

0.5 mg of vitamin B6

0.2 μg of vitamin B12

Vitamin C 10 mg

Biotin 10 μg

Nicotinamide 1.7 mg

50 μg of folic acid

Calcium pantothenate 0.5 mg

Mineral mixture appropriate amount

ferrous sulfate 1.75 mg

Zinc Oxide 0.82 mg

Magnesium carbonate 25.3 mg

potassium phosphate monobasic 15 mg

Dibasic calcium phosphate 55 mg

Potassium citrate 90 mg

100 mg of calcium carbonate

Magnesium chloride 24.8 mg

The composition ratio of the vitamin and mineral mixture is relatively suitable for health functional food, but the composition is mixed in a preferred embodiment, but the mixing ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health functional food manufacturing method Then, the granules can be prepared and used in the preparation of a health functional food composition according to a conventional method.

1-2: Preparation of beverages

100 mg of green seaweed oil of Example 2

1,000 mg citric acid

100 g of oligosaccharides

2 g of plum concentrate

1 g taurine

Add purified water to total 900 mL

After mixing the above ingredients according to the usual health drink manufacturing method, after stirring and heating at 85 ° C for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed and sterilized, then refrigerated. It is used to prepare the functional beverage composition of the present invention.

Preparation Example 2: Preparation of cosmetics

2-1: Softening lotion (skin)

In order to prepare an antibacterial and anti-inflammatory softening lotion containing the green seaweed oil of the present invention, it can be prepared according to a conventional manufacturing method in the cosmetic field by mixing as shown in Table 4 below.

ingredient content (wt%) Blue Sea Oil of Example 2 0.1-30% 1,3-butylene glycol 3.0 glycerin 5.0 Polyoxyethylene (60) hydrogenated castor oil 0.2 ethanol 8.0 citric acid 0.02 sodium citrate 0.06 antiseptic a very small amount Spices a very small amount Purified water To 100

2-2: Nutrient lotion (lotion)

In order to prepare an antibacterial and anti-inflammatory nutrient lotion containing the green seaweed oil of the present invention, it can be prepared according to a conventional manufacturing method in the cosmetic field by mixing as shown in Table 5 below.

ingredient content (wt%) Blue Sea Oil of Example 2 0.1-30% 1,3-butylene glycol 3.0 glycerin 5.0 squalane 10.0 Monooleate polyoxyethylene sorbitan 2.0 Yuchangwood Oil 0.1-30% Polyoxyethylene (60) hydrogenated castor oil 0.2 ethanol 8.0 citric acid 0.02 sodium citrate 0.06 antiseptic a very small amount Spices a very small amount Purified water To 100

2-3: face wash (cleansing foam)

In order to prepare an antibacterial and anti-inflammatory face wash (cleansing foam) containing the green seaweed oil of the present invention, it can be prepared according to a conventional manufacturing method in the cosmetic field by mixing as shown in Table 6 below.

ingredient content (wt%) Blue Sea Oil of Example 2 0.1-30% Sodium N-acylglutamate 20.0 glycerin 10.0 PEG-400 15.0 propylene glycol 10.0 POE (15) Oleyl Alcohol Ether 3.0 Laurine derivatives 2.0 methylparaben 0.2 EDTA-4Na 0.03 Spices 0.2 Purified water To 100

2-4: Nourishing Cream

In order to prepare the antibacterial and anti-inflammatory nutritional cream containing the green seaweed oil of the present invention, it is prepared according to the manufacturing method in the conventional cosmetic field as shown in Table 7 below.

ingredient content (wt%) Blue Sea Oil of Example 2 0.1-30% vaseline 7.0 liquid paraffin 10.0 beeswax 2.0 Polysorbate 60 2.5 Sorbitan sesquioleate 1.5 squalane 3.0 propylene glycol 6.0 glycerin 4.0 triethanolamine 0.5 Xanthan Gum 0.5 tocophenyl acetate 0.1 fragrance, preservative a very small amount Purified water To 100

Preparation Example 3: Preparation of a pharmaceutical formulation

3-1: Preparation of powder

Blue Sea Oil of Example 2 50 mg

lactose 20 mg

After mixing the above ingredients, the powder was prepared by filling in an airtight cloth.

3-2: Preparation of tablets

Blue Sea Oil of Example 2 10 mg

corn starch 100mg

lactose 100mg

magnesium stearate 2mg

After mixing the above ingredients, tablets were prepared by tableting according to a conventional manufacturing method of tablets.

3-3: Preparation of capsules

Blue Sea Oil of Example 2 10 mg

crystalline cellulose 3mg

lactose 14.8mg

magnesium stearate 0.2mg

After mixing the above ingredients, the capsules were prepared by filling in gelatin capsules according to a conventional manufacturing method of capsules.

3-4: Preparation of liquid formulation

Blue Sea Oil of Example 2 20 mg

Lee Seonghwadang 10g

mannitol 5g

Purified water appropriate amount

Add each component to purified water to dissolve it according to a conventional method for preparing a liquid, add an appropriate amount of lemon flavor, mix the above ingredients, add purified water to adjust the total to 100 ml, fill a brown bottle, and sterilize the solution prepared.

3-5: Preparation of injection

Blue Sea Oil of Example 2 10 mg/ml

dilute hydrochloric acid BP until pH 7.6

Main Use Sodium Chloride BP up to 1ml

The green seaweed oil of the present invention was dissolved in an appropriate volume of sodium chloride BP for main use, the pH of the resulting solution was adjusted to pH 7.6 using dilute hydrochloric acid BP, the volume was adjusted using sodium chloride BP for main use, and the mixture was sufficiently mixed. . The solution was filled in a 5 ml Type I ampoule made of clear glass, sealed under an upper grid of air by dissolving the glass, and autoclaved at 120° C. for 15 minutes or more to prepare an injection solution.

Although the present invention has been described as the above-mentioned preferred embodiment, it is possible to make various modifications and variations without departing from the spirit and scope of the invention. It is also intended that the appended claims cover such modifications and variations as fall within the scope of the present invention.

Claims (20)

An antibacterial and anti-inflammatory food composition comprising green seaweed oil as an active ingredient. According to claim 1,
The green seaweed ( Ulva ohnoi ), burdock ( Ulva pertusa ), bent brown seagrass ( Ulva flexousa ), long tong brown seagrass ( Ulva procera ), peony brown seagrass ( Ulva conglobata ), green brown seagrass ( Ulva japonica ), intestinal algae ( Ulva intestinalis ) ), flat green ( Ulva compressa ), spiny ( Ulva prolifera ), lattice ( Ulva clathrata ), leaf green ( Enteromorpha linza ), monostroma nitidum and one or more types selected from Food composition for antibacterial and anti-inflammatory, characterized in that. According to claim 1,
The green seaweed oil is an antibacterial and anti-inflammatory food composition, characterized in that the oil is extracted after performing microwave drying of sea greens. 4. The method of claim 3,
The antibacterial and anti-inflammatory food composition, characterized in that the water content of the green onion after the microwave drying is 3 to 10% by weight. 4. The method of claim 3,
The green seaweed oil is an antibacterial and anti-inflammatory food composition, characterized in that the oil is extracted according to any one method selected from compression method, steam distillation method, cold soaking method, warm soaking method, solvent extraction method, and supercritical carbon dioxide extraction method. 6. The method of claim 5,
The green seaweed oil is an antibacterial and anti-inflammatory food composition, characterized in that it is an oil extracted according to a supercritical carbon dioxide extraction method. 7. The method of claim 6,
Antibacterial and anti-inflammatory food composition, characterized in that the flow rate of carbon dioxide during the supercritical extraction is 50 to 70 ㎖ / min. 7. The method of claim 6,
The supercritical extraction temperature is 45 to 55 ℃, the pressure is 270 to 290 bar antibacterial and anti-inflammatory food composition, characterized in that. According to claim 1,
The seaweed oil is an antibacterial and anti-inflammatory food composition, characterized in that it has antibacterial activity against at least one strain selected from Bacillus subtilis and Escherichia coli . According to claim 1,
The green seaweed oil is an antibacterial and anti-inflammatory food composition, characterized in that it exhibits an effect of inhibiting the expression of inflammatory cytokines TNF-α or IL-1β. According to claim 1,
The composition is an antibacterial and anti-inflammatory food composition, characterized in that in the form of a solution, powder, emulsion, lotion, spray, ointment, aerosol, cream or foam. An antibacterial and anti-inflammatory cosmetic composition comprising green seaweed oil as an active ingredient. An antibacterial and anti-inflammatory pharmaceutical composition comprising green seaweed oil as an active ingredient. (1) drying the green onion to prepare a drying material; and
(2) extracting oil from the dry material; antibacterial and anti-inflammatory food composition comprising a method of manufacturing. 15. The method of claim 14,
The drying is a method of producing a food composition for antibacterial and anti-inflammatory, characterized in that performing microwave drying. 16. The method of claim 15,
The microwave drying is a method for producing an antibacterial and anti-inflammatory food composition, characterized in that it is performed using a microwave dryer of 15 to 20 kW output. 17. The method of claim 16,
The microwave drying is a method for producing an antibacterial and anti-inflammatory food composition, characterized in that it is performed once or twice for 1 to 3 minutes. 18. The method of claim 17,
According to the microwave drying, the method for producing an antibacterial and anti-inflammatory food composition, characterized in that the moisture content of the dried material is 3 to 8% by weight. (1) drying the green onion to prepare a drying material; and
(2) extracting oil from the dry material; method for producing a cosmetic composition for antibacterial and anti-inflammatory comprising a. (1) drying the green onion to prepare a drying material; and
(2) extracting the oil from the dry material; Antibacterial and anti-inflammatory pharmaceutical composition comprising a method for producing a composition.

Images